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Abstract
The proinflammatory transcription factor nuclear factor-κB (NF-κB) has 
emerged as a central player in inflammatory responses and tumor development 
since its discovery three decades ago. In general, aberrant NF-κB activity plays a 
critical role in tumorigenesis and acquired resistance to chemotherapy. This aber-
rant NF-κB activity frequently involves several post-translational modifications of 
NF-κB, including phosphorylation. In this chapter, we will specifically cover the 
phosphorylation sites reported on the p65 subunit of NF-κB and their relationship 
to cancer. Importantly, phosphorylation is catalyzed by different kinases using 
adenosine triphosphate (ATP) as the phosphorus donor. These kinases are fre-
quently hyperactive in cancers and thus may serve as potential therapeutic targets 
to treat different cancers.
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1. Introduction
1.1 Basic nuclear factor-κB (NF-κB) family and signaling pathways
So what is NF-κB? In mammals, NF-κB is a collective term for a small family of 
dimeric transcription factors [comprising p65 (RelA) and RelB, c-Rel, p50/p105 
(NF-κB1), and p52/p100 (NF-κB2)]. All NF-κB proteins share a Rel homology 
domain (RHD), which is responsible for DNA binding and dimerization. Only 
p65, RelB, and c-Rel contain potent transactivation domains within sequences 
from C-terminal to the RHD. Therefore, p50 and p52 cannot act as transcriptional 
activators by themselves. Dimers of these two proteins have been reported to 
repress NF-κB-dependent transcription in vivo, most likely by competing with 
other transcriptionally active dimers. These proteins form homo- and heterodi-
mers, and their activity is regulated by the canonical or alternative pathways 
described as following [1]. A simple diagram of canonical NF-κB signaling, which 
will be the focus of this chapter, is shown in Figure 1. The canonical pathway is 
activated by multiple stimuli, including proinflammatory cytokines (e.g., tumor 
necrosis factor, TNF; interleukin 1, IL-1), and the components of the bacterial 
wall (Lipopolysaccharide, LPS). Exterior signals lead to the phosphorylation 
and degradation of the inhibitory complex IκB, which is modulated by the IκB 
kinase (IKK), and its degradation allows for the release of the typical NF-κB 
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heterodimer, p65/p50, to translocate into the nucleus. NF-κB binds to its cognate 
DNA elements and can transcriptionally activate different target genes among 
which 200–500 genes have been implicated in cell survival/apoptosis, cell growth, 
immune response, and inflammation [2].
The alternative or noncanonical pathway is activated by the members of the 
TNF cytokine family, such as B-cell activating factor (BAFF), cluster of differentia-
tion 40 ligand (CD40L), receptor activator of nuclear factor-κB ligand (RANKL), 
and lymphotoxin-β2 (LTβ2), and requires recruitment of the p52/RelB dimers to 
activate transcription. Firstly, activation of NIK (NF-κB-inducing kinase) leads to 
Figure 1. 
Pathway of canonical and non-canonical NF-κB signaling. Under the canonical pathway of NF-κB signaling, 
activation of the NF-κB is initiated by a stimulus resulting in phosphorylation and subsequent proteasomal 
degradation of IκBα. This allows the release of the p65/p50 heterodimer into the nucleus, where they can bind 
to their cognate DNA elements and promote NF-κB target gene expression [1]. On the other hand, under 
noncanonical activation of NF-κB, NIK (NF-κB-inducing kinase) leads to activation of IKKα in this pathway. 
Subsequent phosphorylation of the NF-κB1 precursor molecule, p100, triggers partial proteolysis giving rise to 
p52, which preferentially dimerizes with RelB. This allows translocation of p52/RelB to the nucleus where they 
can bind to cognate DNA elements and promote gene transcription [1]. Figure adapted and simplified from 
Hoesel et al. [103].
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activation of IKKα in this pathway. This event leads to the subsequent phosphoryla-
tion of the NF-κB1 precursor molecule, p100, and triggers partial proteolysis to give 
rise to p52, which preferentially dimerizes with RelB [1]. The p52/RelB heterodimer 
then translocates to the nucleus where they can bind to cognate DNA elements and 
promote gene transcription (Figure 1).
1.2 Important role of NF-κB in cancer
NF-κB was first discovered by Dr. Ranjan Sen in 1986 [3]. This family of 
transcription factors plays important roles in the regulation of apoptosis, prolif-
eration, inflammation, and immune response in both normal and cancer cells. 
Generally, in normal cells, the central transcription factor NF-κB is transiently 
activated in response to certain stimuli. However, cancer cells usually exhibit 
sustained activation of NF-κB [4, 5] which significantly contributes to their 
survival. Moreover, NF-κB activity plays critical roles in many of the well-known 
“hallmarks” of cancer, via its regulation of target genes involved in tumor cell pro-
liferation, suppression of apoptosis, activation of angiogenesis as well as induction 
of the epithelial-to-mesenchymal transition (EMT) phenotype, a critical step 
in metastasis [6]. Constitutively active NF-κB has been found in many types of 
cancer. For instance, in thyroid cancer, oncogenic proteins including “rearranged 
during transfection” (RET), “Rat Sarcoma” (RAS), and “v-Raf murine sarcoma 
viral oncogene homolog B” (BRAF) were shown to induce NF-κB activation, 
which in turn activated proliferative and antiapoptotic signaling pathways [7]. 
Moreover, in renal cell carcinoma (RCC), NF-κB is constitutively activated. The 
phosphorylated p65, a major subunit of NF-κB, exhibited a significant increase in 
the RCC samples compared with corresponding normal tissues [8]. Furthermore, 
Nogueira et al. showed that in glioblastoma (GBM), deletion of IκB showed a 
phenotype similar to that of epidermal growth factor receptor (EGFR) amplifica-
tion in the pathogenesis of GBM. This was also correlated with low survival rates 
in affected patients [2].
Importantly, our laboratory also found that in colon cancer, NF-κB can be acti-
vated by the Y-box protein 1 (YBX1), a critical event correlated with increased colon 
cancer cell proliferation and anchorage-independent growth [9, 10]. Additionally, 
in pancreatic cancer, a mutant oncogenic KrasG12D (glycine to aspartic acid) muta-
tion induced positive feedback loops of interleukin 1α (IL-1α) and p62 expression to 
sustain constitutive IKKβ (inhibitor of NF-κB kinase subunit β)/NF-κB activation [11]. 
In breast cancer, moderately elevated NF-κB led to chronic inflammatory conditions 
that result in some cells escaping immune surveillance [12]. Additionally, NF-κB 
activation was shown to upregulate the expression of cyclin D1, cyclin-dependent 
kinase 2 (CDK2), and c-Myc, which drives cell cycle progression and causes uncon-
trolled cell proliferation [13]. Moreover, in breast cancer, NF-κB has been shown to 
induce and stabilize the expression of EMT markers (Snail and twist-related pro-
tein1) [14], a pivotal process in tumor metastasis. In addition to the role of NF-κB 
in solid tumors as described thus far, Gasparini et al. has thoroughly reviewed the 
important tumorgenic role of NF-κB in hematological malignancies, including 
acute lymphocytic lymphoma (ALL), acute myeloid leukemia (AML), chronic lym-
phocytic leukemia (CLL), chromic myeloid leukemia (CML), B lymphomas, diffuse 
large B-cell lymphomas (DLBCLs), Hodgkin’s lymphoma, adult T-cell lymphomas 
(ATLL), anaplastic large-cell lymphomas (ALCL), and multiple myeloma, which 
will not be further discussed in this chapter [15]. Overall, these studies highlight a 
prominent role of dysregulated NF-κB in multiple aspects of cancer progression in 
both solid tumors and hematological malignancies.
Adenosine Triphosphate in Health and Disease
4
2. Role of phosphorylation of NF-κB in cancer
2.1  Phosphorylation of the p65 subunit of NF-ĸB and the role of its kinases  
in cancer
Phosphorylation is a critical modification for NF-κB activation and plays an indis-
pensable role in the regulation of its target genes. Moreover, as mentioned above, 
many of these target genes contribute to the hallmarks of cancer such as cellular 
proliferation, antiapoptosis as well as enhanced angiogenesis via vascular endothelial 
growth factor expression, among others [6]. Thus, understanding how phosphoryla-
tion of NF-κB contributes to these cancer phenotypes is a critical step in effectively 
limiting NF-κB activity [16]. Generally speaking, phosphorylation requires phos-
phorus which is supplied by the donor molecule adenosine tri-phosphate (ATP). 
Although several members of the NF-κB family of proteins are reported to be 
subjected to phosphorylation, p65 stands out as the most frequently modified sub-
unit (Table 1). Furthermore, scientists have found that p65 can be phosphorylated 
by a variety of different kinases, some of which are themselves frequently overactive 
in cancer. For instance, p65 phosphorylation at serine 536 (S536) by IKKβ has been 
shown to be critical for TNFα-induced transformation of mouse epidermal cells [17]. 
Additional studies have also reported a role for p65 S536 phosphorylation in mediat-
ing expression of matrix metalloproteinase 1 (MMP-1) in lymphomas, wherein high 
MMP-1 expression correlated with lymphatic invasion and lymph node metastasis 
[18]. Another study with an immortalized prostate cell line, PNT1a, showed a role for 
phosphorylated S536 of p65 in cell motility and transformation [19].
As mentioned above, phosphorylation events on NF-κB are mediated by a 
variety of kinases. It is therefore unsurprising that the action of these kinases has 
been tightly regulated to maintain normal cellular function. However, deregulation 
Known phosphorylation 
sites of p65
Cancers involved Cell line discovered References
S205 No cancers currently known HEK 293 cells [104]
T254 Breast cancer BT20 and MCF-7 
cells
[105]
S529 Breast cancer HeLa cells [33]
S536 Bone cancer HeLa and BC-3 cells [35]
S276 Head and neck cancers, breast 
cancer
HNSCC cells [34]
S281 No cancers currently known MEF cells [106]
S311 No cancers currently known HEK 293 and MEF 
cells
[107]
T435 No cancers currently known SiHa cells [108]
S468 No cancers currently known HeLa cells [109]
T505 No cancers currently known NARF2 and Hs68 
cells
[110]
S535 No cancers currently known HeLa cells [111]
S316 No cancers currently known HEK 293 cells [41]
S547 No cancers currently known HEK 293 cells [112]
Table 1. 
List of known phosphorylation sites on the p65 subunit of NF-κB and their relationship to cancer.
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of kinase activity can have detrimental downstream effects, which also involves the 
aberrant activation of NF-κB and its target genes to promote a cancer phenotype. 
Several kinases have been shown to have critical roles in the regulation of the p65 
subunit of NF-κB. For example, glycogen synthase kinase 3 beta (GSK3β) and 
TRAF-associated NF-κB activator TBK1 ((TANK)-binding kinase 1) have been 
shown to be critical activators of NF-κB signaling [20, 21] by targeting p65 for 
phosphorylation on S536. This phosphorylation leads to enhanced NF-κB transac-
tivation both in vitro and in vivo [22–24]. Another well-known kinase involved in 
modifying p65 is protein kinase A (PKAc). PKAc is typically activated following 
IκBα-degradation, leading to PKAc-mediated phosphorylation of p65 on S276 
[25]. This phosphorylation event causes recruitment of histone acetyltransferases 
including cAMP response element-binding (CREB)-binding protein (CBP) and 
p300. The net effect is displacement of p50-histone deacetylase (HDAC)-1 complex 
from DNA, which increases p65 transactivation ability [26, 27]. Other kinases can 
also phosphorylate p65 at S276. These include mitogen- and stress-activated protein 
kinase-1 and 2 (MSK1, 2), proto-oncogene serine/threonine-protein kinase PIM-1 
(PIM-1), ribosomal s6 kinase (RSK) p90, and protein kinase C α (PKCα) [28–31]. 
Moreover, casein kinase II (CK2), which phosphorylates p65 on S529, has been 
implicated in breast cancer [32, 33]. Another study demonstrated a role for p65 S276 
phosphorylation by protein kinase A (PKA) in promoting a malignant phenotype 
in head and neck squamous cell carcinoma (HNSCC). Here, the authors found that 
S276 phosphorylation was prevalent in the nucleus of HNSCC samples but cytoplas-
mic in normal mucosa. Furthermore, this TNF-α-induced nuclear p65-S276 phos-
phorylation was significantly inhibited by the PKA inhibitor H-89, which in turn 
suppressed NF-κB activity, target gene expression, cell proliferation, and induced 
cell death via G1/S phase arrest [34]. Other p65-targeting kinases implicated in 
cancer include cell division protein kinase 6 (CDK6) and PIM-1, which phosphory-
late p65 at S536 and S276, respectively [29, 35]. Both PIM1 and CDK6 have been 
shown to be overexpressed in a variety of cancers including hematological cancers, 
prostate cancer, pancreatic cancer, gastric cancer, head and neck cancer, liver 
cancer, glioblastomas, medulloblastomas, colon cancer, and lung cancers [36–39]. 
However, their exact roles in regulating p65 phosphorylation in these cancers are 
yet to be understood. In gastric cancer cells, Aurora Kinase A (AURKA) was also 
shown to phosphorylate S536 in in vivo and in vitro models [40] whereby overex-
pression of AURKA induced a significant increase in NF-κB p65 and phospho-p65 
(S536) protein levels. Interestingly, protein kinase C δ (PKCδ), a member of novel 
PKC isoforms, has also been implicated in a number of cancers including breast, 
pancreatic, prostate, and melanoma tumor cells but has been shown to regulate p65 
transactivation in a phosphorylation-independent manner [41]. Our laboratory has 
also recently reported a novel phosphorylation site on S316 of p65, a modification 
mediated by the kinase CKII [41]. We showed that S316 phosphorylation was neces-
sary for NF-κB activation and target gene expression. Collectively, these examples 
indicate the importance and sophistication of p65 phosphorylation and their cor-
responding kinases in regulating NF-κB signaling in the context of cancer.
2.2  Importance and effects of phosphorylation of p65 in modulating 
chemoresistance
Several studies have indicated a role for NF-κB hyperactivity in the development 
of resistance to chemotherapeutics via downregulation of antisurvival and upregu-
lation of prosurvival target genes and pathways [42–44]. In one study for example, 
gemcitabine-resistant pancreatic cancer cells were rendered sensitive to gemcitabine 
upon knockdown of p65 [42]. These and other accounts of NF-κB-mediated 
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chemoresistance have been extensively reviewed by others such as Li, Sethi, and 
Godwin et al., which will not be further discussed in this chapter [45, 46]. However, 
the specific contribution of dysregulated p65 phosphorylation to chemoresistance 
is less well understood and requires further exploration. Nonetheless, a few reports 
suggest that upstream kinases involved in chemoresistance can modulate p65 
phosphorylation levels in this context. For instance, siRNA-mediated depletion of 
IKKα in HT1080 human fibrosarcoma cells was shown to decrease phosphorylation 
of p65 in response to doxorubicin, thus severely impairing the ability of doxorubi-
cin to initiate NF-κB DNA-binding activity. These findings suggest that IKKα plays 
a critical role in NF-κB-mediated chemoresistance in response to doxorubicin and 
potentially serves as a therapeutic target for improving chemotherapeutic response 
[47]. Other studies have shown that p65, in a hyperphosphorylated state, can be 
correlated with resistance to thymidylate synthases and irinotecan in stomach and 
colon cancers, respectively [44, 48, 49]. Doxorubicin resistance in lung cancer 
has also been correlated with p65 S536 phosphorylation states [47]. Additionally, 
multiple myelomas have exhibited increased p65 S536 phosphorylation within 
melphalan- or doxorubicin-resistant cells [50].
3. p65 modifying kinases as potential therapeutic targets
3.1 Current therapeutics used to treat cancers with constitutive NF-κB activity
The NF-κB pathway is widely considered an attractive therapeutic target in a 
broad range of cancers. Yet, despite the efforts to develop NF-κB inhibitors, none 
has been clinically approved. This is largely due to immune-related toxicities associ-
ated with global NF-κB suppression [51]. Furthermore, the high complexity of the 
NF-κB signaling network presents another unique challenge for developing specific 
NF-κB inhibitors. To further complicate matters, some standard anticancer agents 
can inadvertently activate the NF-κB pathway via induction of proinflammatory 
cytokines such as IL-1β and TNF-α and cellular stressors such as reactive oxygen 
species (ROS), or by activating DNA-repair mechanisms [52]. Finally, constitutive 
NF-κB activity can also be achieved via secreted cytokines and chemokines from 
inflammatory cells within the tumor microenvironment [52]. Taken together, 
consideration of all these factors is imperative when strategizing the development 
of the most effective and least toxic anticancer agents.
Currently, the use of NF-κB inhibitors has mainly been combined with other 
agents [47, 50]. Some of these combinatorial therapies have shown promising 
effectiveness and have been made it as far as the clinical trial phase. For example, 
combination of irinotecan with the proteasome and NF-κB inhibitor bortezomib 
was shown to increase sensitivity of colon cancer cells to irinotecan [53]. A sepa-
rate study showed that bortezomib could sensitize non-small cell lung cancer 
(NSCLC) cells to sodium butyrate, which acts to inhibit histone deacetylases [54].  
Moreover, several clinical trials testing the efficacy of inhibitors against IKK to 
target solid tumors have been undertaken. For example, perturbation of IKKβ 
with the inhibitory ML120B led to synergistic enhancement of vincristine cyto-
toxicity in lymphoma. These results implicate IKK disruption using inhibitors 
as a useful adjunct therapy with standard chemotherapeutics. Other attempted 
trials using IKK inhibitors, such as CHS-828, EB-1627, and IMD-1041, as single 
or combinatorial agents unfortunately produced toxicity concerns for patients 
[55–57].
Other examples of combinatorial therapies include the use of NF-κB inhibi-
tors Bay11-7082 and sulfasalazine in combination with more commonly used 
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chemotherapeutics such as 5-fluorouracil and cisplatin to synergistically reduce 
colon cancer cell growth [58]. Other indirect means of targeting NF-κB such as 
inhibition of upstream kinases have also shown promise. For instance, one study 
using pancreatic cancer cells showed that inhibition of GSK3β by a small molecule 
inhibitor reduced phosphorylation of p65 at S536 resulting in decreased NF-κB 
activity and cell growth [59]. Another study with the chemical compound ursolic 
acid showed reduced p65 phosphorylation via inhibition of IKKβ, which impaired 
overall cell growth in leukemia cell lines [60]. Other studies with proteasome 
inhibitors, including Tosyl phenylalanyl chloromethyl ketone (TPCK) and Tosyl-L-
lysyl-chloromethane hydrochloride (TLCK), demonstrated that not only do these 
inhibitors target IKKβ, but they were also able to reduce overall phosphorylation 
levels of NF-κB [61, 62]. In summary, these studies suggest there may be many 
benefits to targeting hyperactive NF-κB signaling and, in particular, the kinases that 
regulate NF-κB in various cancers.
3.2 Benefits and pitfalls for targeting kinases in cancers
The development of small-molecule kinase inhibitors for the treatment of can-
cer has continued to be of intense interest. Notably, many inhibitors have received 
FDA approval with approximately another 150 are in preclinical and clinical 
phase trials. Despite these important advances, many factors have confounded the 
clinical efficacy of these kinase-targeted drugs including the challenges of tumor 
heterogeneity and microenvironment as well as the emergence of mutations that 
confer drug resistance. Another major challenge of kinase inhibition is that of the 
development of adverse side effects. Some classic examples of this include derma-
tologic complications and cardiotoxicity associated with inhibition of EGFR and 
vascular endothelial growth factor receptor (VEGFR), respectively. Furthermore, 
there is an urgent need to develop relevant models of resistance in response to 
kinase inhibitors in efforts to overcome this resistance via potential synergistic 
combinatorial therapies.
Another critical issue facing clinical trial design with kinase-targeted agents is 
that of determining the types of tumors that are most likely to respond to specific 
kinase inhibitors and thus identify the subsets of patients who will likely benefit 
from these treatments. To combat this issue, many studies have been dedicated to 
identifying certain “kinase dependencies” in cancer cells that would make them 
more susceptible to inhibition. These so-called dependencies are primarily based 
on the existence of constitutively activate kinases achieved by gene mutation, 
amplification, or fusion. Among the potential approaches to identifying signa-
tures of kinase dependency are proteomic profiling, next-generation sequencing 
and various applications utilizing phospho-specific antibodies against numerous 
specific kinase substrates. Additional mechanisms of kinase dependency include 
impairment of the function of phosphatases, the negative regulators of phos-
phorylation as is the case with mutations in the phosphatase and tensin homolog 
(PTEN) tumor suppressor gene. The consequence of PTEN loss is signal propaga-
tion through downstream kinases such as Akt. Moreover, growing evidence from 
isogenic human and mouse models also suggests that this type of indirect avenue 
of kinase dependency may be analogous to direct, activating mutations in the 
kinases themselves.
Finally, there are also cases in which the beneficial effect of a kinase inhibi-
tor is counteracted by an additional genetic lesion in a compensatory signaling 
pathway. Therefore, studies to identify such secondary events are urgently needed. 
Taken together, these evidences underscore the critical need to optimize the use of 
kinase inhibitors against cancers by continued detailed molecular characterization 
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of tumor tissues. It will be critical to develop new compounds that circumvent 
acquired resistance to the first-generation kinase inhibitors for patients with refrac-
tory disease.
3.3  Cutting edge therapeutics for treating cancers with constitutively active 
kinases
Since the mid-1970s, numerous studies have highlighted a crucial role for 
kinases in promoting tumorigenesis and metastasis [63–67]. This is of no surprise, 
since a clear majority of protein kinases promote critical cellular functions perti-
nent to cancer progression, including cell proliferation, survival, and migration 
[68–72]. Hence, targeting mutated, overexpressed, or hyperactive kinases repre-
sents an important and promising clinical niche for developing drugs for cancer 
therapy [67, 73, 74]. Interestingly, inhibitors against kinases account for approxi-
mately 25% of all current drug discovery efforts. So far, ~37 inhibitors with activity 
targeted to one or multiple kinases have been approved for clinical use [67, 75]. 
These range from highly selective monoclonal antibodies to more broad-spectrum 
synthetic or natural small molecules that have achieved a significant increase in 
patient survival rate in cancers [67]. For example, treatment with imatinib and 
dasatinib, which are highly potent and selective tyrosine kinase inhibitors against 
BCR-ABL, produces more favorable outcomes compared to conventional cytotoxic 
therapy for patients with chronic myeloid leukemia (CML) [76–78]. Similarly, 
broad-spectrum inhibitors have also been used with great success. For example, 
CHIR-258, which targets multiple kinases, inhibits VEGFR, platelet-derived 
growth factor receptor (PDGFR), FMS-like tyrosine kinase-3 (FLT-3), mast/stem 
cell growth factor receptor (c-Kit), and fibroblast growth factor receptor (FGFR) 
in multiple myeloma patients and is most effective for killing tumors harboring 
the translocation t [4, 14] (p16.3;q32.3) with increased expression and activating 
mutations of FGFR3 [79–81].
Some other major inhibitors to enter the market include those targeting 
key oncogenic kinase drug targets such as ERBB2 (e.g., afatinib), HER2 (e.g., 
trastuzumab), and VEGFRs (e.g., sorafenib, a small molecule inhibitor used 
for the treatment of renal cell, liver. and thyroid cancers) [82–87]. Another 
successful targeting strategy has been the use of a monoclonal antibody against 
VEGFR (bevacizumab). Bevacizumab is used in combination with chemother-
apy to treat patients with metastatic colon cancer, and its widespread use has 
resulted in significant improvement in survival outcomes [88]. Other examples 
include inhibitors against Kit, PDGFRs, proto-oncogene tyrosine-protein 
kinase Src (SRC), mechanistic target of rapamycin and FK506-binding protein 
12-rapamycin-associated protein 1 (mTOR), phosphatidylinositol-4,5-bispho-
sphate 3-kinase catalytic subunit alpha (PIK3CA), serine/threonine-protein 
kinase B (PKB or Akt)—Raf (BRAF), and epidermal growth factor receptor 
(EGFR) (e.g., cetuximab, panitumumab), all of which act to activate signifi-
cant tumor cell signaling pathways such as NF-ĸB [67, 89]. For instance, several 
FDA-approved kinase inhibitors, although not perceived as direct NF-ĸB 
inhibitors, have been shown to suppress NF-κB signaling [89]. These include 
inhibitors targeting EGFR in breast and lung cancer, Akt in breast cancer, 
GSK-3β in pancreatic cancer, NIK in melanoma, BRAF in multiple myeloma, and 
IKK in brain and liver cancer [89–91]. Specifically, GSK2118436, PLX4720, 
sorafenib, and PLX4032 are all drugs which are currently being used to target 
B-RafV600E in advanced cancers with elevated NF-ĸB activity [73, 92–94]. 
Finally, small molecule inhibitors targeting Akt, which include perifosine, 
GSK690693, VQD002, and MK2206, are also being tested clinically [95, 96].  
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In summary, these studies highlight the importance of inhibition of distinct 
kinase signaling pathways as a means of minimizing cytotoxic effects on non-
cancerous cells, thus bestowing selective killing of tumor cells and improving 
patient clinical outcomes.
4. Conclusion and future directions
In summary, this chapter highlights a significant role of NF-ĸB phosphorylation 
in driving the initiation and progression of several cancers as well as chemoresis-
tance to first-line therapies. Furthermore, we emphasized the relationship between 
p65 phosphorylation and the role that constitutively active kinases play in promot-
ing the cancer phenotype, via utilization of ATP as the phosphate donor. Finally, we 
underlined the well-established therapeutic potential of targeting these kinases in 
the treatment of various cancers. Despite these encouraging data, we acknowledge 
that the difficulties with drug resistance and toxicity continue to present critical 
challenges for the use of kinase inhibitors in both clinical and experimental oncology. 
Furthermore, issues related to the inadequate understanding of the selectivity of 
the kinase inhibitors have also plagued the successful clinical utility of these inhibi-
tors. Nevertheless, a key challenge for overcoming this enigma is to identify the 
most efficacious, complementary, and least toxic combinations of kinase inhibitors 
for targeted cancer treatment [97, 98]. This will likely lead to the development of 
multimodal treatment initiatives that evade the treatment-related drug resistance. 
Finally, it is well known that cancers have heterogeneous populations of cells, and 
these may differentially contribute to chemoresistance [99, 100]. To address this, 
many efforts are underway to eliminate cancer stem cells as main culprits of this 
intrinsic heterogeneity, which will undoubtedly improve our understanding of 
better drug design and efficiency [101, 102].
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